⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNXT News
RenovoRx, Inc. Common Stock
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
globenewswire.com
RNXT
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
globenewswire.com
RNXT
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
globenewswire.com
RNXT
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
globenewswire.com
RNXT
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
globenewswire.com
RNXT
Form 8-K
sec.gov
RNXT
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
RNXT
Form 8-K
sec.gov
RNXT
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
globenewswire.com
RNXT
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
globenewswire.com
RNXT